Theravance Biopharma, Inc. (NASDAQ:TBPH) Sees Significant Drop in Short Interest

Theravance Biopharma, Inc. (NASDAQ:TBPH) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 6,430,000 shares, a decrease of 14.5% from the March 31st total of 7,520,000 shares. Currently, 14.7% of the shares of the stock are sold short. Based on an average daily volume of 367,200 shares, the short-interest ratio is currently 17.5 days.

Theravance Biopharma Trading Down 1.4 %

Theravance Biopharma stock opened at $8.99 on Tuesday. The stock has a market cap of $436.55 million, a P/E ratio of -9.27 and a beta of 0.36. The company has a 50-day moving average price of $9.08 and a 200 day moving average price of $9.68. Theravance Biopharma has a 12-month low of $8.21 and a 12-month high of $11.98.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The business had revenue of $17.57 million during the quarter, compared to analyst estimates of $17.49 million. Theravance Biopharma had a negative net margin of 96.12% and a negative return on equity of 19.31%. As a group, analysts forecast that Theravance Biopharma will post -0.84 EPS for the current year.

Wall Street Analysts Forecast Growth

TBPH has been the topic of several research analyst reports. BTIG Research initiated coverage on Theravance Biopharma in a report on Friday, April 12th. They issued a “buy” rating and a $21.00 price objective on the stock. Evercore ISI cut Theravance Biopharma from an “outperform” rating to an “inline” rating in a research report on Monday, January 8th.

Institutional Trading of Theravance Biopharma

Institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. boosted its position in shares of Theravance Biopharma by 324.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 4,402 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Theravance Biopharma by 31.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,330 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 2,227 shares during the period. Gerber LLC acquired a new position in Theravance Biopharma in the 4th quarter valued at about $112,000. Simplicity Solutions LLC purchased a new stake in Theravance Biopharma during the fourth quarter worth about $141,000. Finally, Bleakley Financial Group LLC acquired a new stake in shares of Theravance Biopharma during the fourth quarter worth about $141,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.